Skip to main content
Benaroya Research Institute

Main navigation

  • About BRI
    • Leadership
    • Faculty
    • Administrative Leaders
    • Together We Discover
    • Contact Us
  • Our Research
    • Centers of Discovery
      • Fundamental Immunology
      • Translational Immunology
      • Interventional Immunology
      • Systems Immunology
        • Bioinformatics at BRI
    • Labs
    • Biorepositories
      • Be a Part of BRI Research
    • Clinical Research
      • Allergies & Asthma Clinical Research
    • Core Labs
      • Cell And Tissue Analysis Group
      • Genomics Core
      • Human Immunophenotyping Core
      • Protein and Tetramer Core
        • Protein & Tetramer Core Ordering
    • Immune Tolerance Network
    • Scientific Publications
    • Scientific Meetings at BRI
      • Asthma Research Symposium
      • BRI Immunology Symposium: New Horizons in Immunity and Disease
      • Cross Autoimmunity Prevention Symposium
  • Collaborations with BRI
    • Opportunities for Collaboration
    • Technology Available for Licensing
  • News
    • Press Releases
  • Support our Research
    • Donate Now
    • BRI Events
      • BRI Open House
      • Immunology to Change Lives

Utility Menu

  • Immunology Learning Center
  • Autoimmune Life Blog
  • Careers
  • Clinical Research at VMMC
  • Donate
  • Search
    • Jul 2025

      Expanding the Case for Hybrid Insulin Peptides in Type 1 Diabetes.

      Diabetes
      Cerosaletti K, Kent SC
    • Mar 2025

      A molecular basis for milk allergen immune recognition in eosinophilic esophagitis.

      J Allergy Clin Immunol
      Dilollo J, Hu A, Qu H, Canziani KE, Clement RL, McCright SJ, Shreffler WG, Hakonarson H, Spergel JM, Cerosaletti K, Hill DA
    • Oct 2024

      Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy.

      J Autoimmun
      Tewari R, Yang SJ, McClain ED, Hu A, Mortensen E, DeSchmidt A, Chen J, Kancharla A, Singh AK, James EA, Burman BE, Siddique A, Rawlings DJ, Patel C, Cerosaletti K, Buckner JH
    • Jul 2024

      IKZF1 and UBR4 gene variants drive autoimmunity and TH2 polarization in IgG4-related disease.

      J Clin Invest
      Liu Q, Zheng Y, Sturmlechner I, Jain A, Own M, Yang Q, Zhang H, Pinto E Vairo F, Cerosaletti K, Buckner JH, Warrington KJ, Koster MJ, Weyand CM, Goronzy JJ
    • Jun 2024

      Germline-like TCR-α chains shared between autoreactive T cells in blood and pancreas.

      Nat Commun
      Linsley PS, Nakayama M, Balmas E, Chen J, Barahmand-Pour-Whitman F, Bansal S, Bottorff T, Serti E, Speake C, Pugliese A, Cerosaletti K
    • Feb 2024

      GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

      JCI Insight
      Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H, Hunt M, Drow T, Tewari R, Cook PJ, Yang SJ, Cerosaletti K, Schweinoch D, Guiastrennec B, James E, Patel C, Chen TF, Buckner JH, Rawlings DJ, Wickham TJ, Mueller KT
    • Oct 2023

      Self-reactive germline-like TCR alpha chains shared between blood and pancreas.

      Res Sq
      Linsley P, Nakayama M, Balmas E, Chen J, Pour F, Bansal S, Serti E, Speake C, Pugliese A, Cerosaletti K
    • Oct 2023

      A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.

      Diabetologia
      Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC, AG019-T1D-101 Trial Investigators
    • Sep 2023

      Shifts in isoform usage underlie transcriptional differences in regulatory T cells in type 1 diabetes.

      Commun Biol
      Newman JRB, Long SA, Speake C, Greenbaum CJ, Cerosaletti K, Rich SS, Onengut-Gumuscu S, McIntyre LM, Buckner JH, Concannon P
    • Sep 2023

      Proinflammatory islet antigen reactive CD4 T cells are linked with response to alefacept in type 1 diabetes.

      JCI Insight
      Balmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley PS, Cerosaletti K
    • Mar 2023

      PTPN22 R620W gene editing in T cells enhances low avidity TCR responses.

      Elife
      Anderson W, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Buckner JH, Rawlings DJ
    • Oct 2022

      Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models.

      Sci Transl Med
      Yang SJ, Singh AK, Drow T, Tappen T, Honaker Y, Barahmand-Pour-Whitman F, Linsley PS, Cerosaletti K, Mauk K, Xiang Y, Smith J, Mortensen E, Cook PJ, Sommer K, Khan I, Liggitt D, Rawlings DJ, Buckner JH
    • Jul 2022

      IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation.

      Front Immunol
      Lambert K, Diggins KE, Jones BE, Hundhausen C, Maerz MD, Hocking AM, Sanda S, Greenbaum CJ, Linsley PS, Cerosaletti K, Buckner JH
    • Mar 2022

      Single Nucleotide Variant in FAS Associates With Organ Failure and Soluble Fas Cell Surface Death Receptor in Critical Illness.

      Crit Care Med
      Mikacenic C, Bhatraju P, Robinson-Cohen C, Kosamo S, Fohner AE, Dmyterko V, Long SA, Cerosaletti K, Calfee CS, Matthay MA, Walley KR, Russell JA, Christie JD, Meyer NJ, Christiani DC, Wurfel MM
    • Jan 2022

      HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy.

      J Clin Invest
      Kanchan K, Grinek S, Bahnson HT, Ruczinski I, Shankar G, Larson D, Du Toit G, Barnes KC, Sampson HA, Suarez-Farinas M, Lack G, Nepom GT, Cerosaletti K, Mathias RA

Pagination

Current page 1 Page 2 Page 3 Next page Next › Last page Last »
Benaroya Research Institute

1201 Ninth Avenue
Seattle, WA 98101-2795
(206) 342-6500

facebook Bluesky instagram linkedin youtube threads
Resources
  • Support our Research
  • Subscribe to News
  • Careers
  • Contact Us
  • Research Conflicts of Interest
  • Research Security Program
  • Terms of Use
  • Research Requirements
If you would like to contact us regarding the accessibility of our website, please contact us at 206-342-6500 or email communications@benaroyaresearch.org.
© 2025 Benaroya Research Institute, a 501(c)(3) nonprofit organization
Close Close